Goldman Sachs Overhauls Conviction Lists, Adding Vertex and Three European Names — BigGo Finance
Goldman Sachs updated its Conviction Lists, adding Vertex Pharmaceuticals (VRTX) to the U.S. list and Adyen, RWE, and Talanx to the European list. Vertex is seen as well-positioned for long-term growth, while Adyen has a 77% upside target. RWE and Talanx also have significant upside potential according to Goldman's analysts.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the explicit rotation: Vertex and three European names are added with bullish theses and targets, while Interactive Brokers and several European names are removed.
Market read
This is a sentiment and positioning catalyst via a major bank’s conviction-list rotation, with explicit targets for the European additions.
What to watch
Traders may overreact to list inclusion/removal; without new earnings, trial, or deal catalysts, price impact may fade quickly and be dominated by sector tape and macro rates.
Background
The article describes Goldman Sachs refreshing its highest-conviction stock picks in the U.S. and Europe, adding and removing specific large-cap names.
Ticker impact
Goldman added Vertex Pharmaceuticals to its U.S. conviction list, citing long-term growth across multiple cystic fibrosis, pain, kidney and hematology opportunities.
Mild near-term support for VRTX sentiment; follow-through depends on broader biotech tape and any subsequent analyst revisions.
The article provides a specific list change and a bullish thesis, but no new Vertex financials, trial readout, or deal terms.
Goldman removed Interactive Brokers from its U.S. conviction list, leaving 23 names after the refresh.
Slight negative bias for IBKR near term, with limited durability absent other catalysts.
The news is a concrete list change, but the article does not cite a new IBKR-specific deterioration or event.
Goldman added Talanx to its European list with a €141 target, describing Retail International as an underappreciated growth engine.
Mild-to-moderate upside bias for TLX, contingent on how investors weigh reinsurance pricing and execution risk.
The article provides a target and catalysts, but the US ticker for Talanx is not explicitly confirmed in the text.
Market effects
Payments (Adyen) and grid/energy infrastructure (RWE) get AI and data-center demand read-through; insurance (Talanx) gets a growth-engine framing.
European large-cap sentiment could tilt toward the Netherlands/Germany names included, while excluded names may see relative underperformance.
US and European conviction-list rotations can influence cross-Atlantic positioning in large-cap growth and infrastructure themes.
Counterpoint
Conviction-list changes may reflect portfolio construction and relative valuation rather than new company-specific information, limiting follow-through.
Key entities
- bankGoldman Sachs
Issuer of the U.S. Conviction List and European Directors' Cut list refresh.
- companyVertex Pharmaceuticals
Added to Goldman’s U.S. conviction list with a long-term growth thesis.
- companyInteractive Brokers
Removed from Goldman’s U.S. conviction list.
- companyAdyen
Added to Goldman’s European list with an AI-commerce and platform differentiation thesis.
- companyRWE
Added to Goldman’s European list with a €75 target and re-rating narrative.
